A mapping for managers: open innovation for R&D intensive SMEs in the life sciences sector

被引:9
作者
Marangos, Stefanos [1 ]
Warren, Lorraine [2 ]
机构
[1] Bournemouth Univ, Dept Leadership Strategy & Org, Sch Business, Bournemouth, Dorset, England
[2] Massey Univ, Sch Management, Innovat & Entrepreneurship, Palmerston North, New Zealand
关键词
SME; CEOs; Strategies; Open innovation; Life sciences; R&D intensive; BIO-PHARMACEUTICAL INDUSTRY; INBOUND OPEN INNOVATION; HIGH-TECH SMES; ABSORPTIVE-CAPACITY; DRUG DISCOVERY; SMALL FIRMS; TECHNOLOGY; KNOWLEDGE; NETWORKS; PERFORMANCE;
D O I
10.1108/EJIM-12-2015-0133
中图分类号
F [经济];
学科分类号
02 ;
摘要
Purpose - The purpose of this paper is to examine what strategies the CEOs of research and development (R&D) intensive small/medium enterprises (SMEs) in the life sciences sector carry out in regard to open innovation (OI), as R&D costs continue to rise, placing pressure on innovation managers. Design/methodology/approach - A qualitative study was carried out, consisting of 30 semi-structured interviews with CEOs of small R&D intensive SMEs in the life sciences sector. The authors analysed the key factors identified by the CEOs in relation to their OI strategies. Findings - SMEs adopt a range of OI strategies and collaborations, subject to certain conditions. A multilevel mapping developed from the analysis connects actors to the wider domain, setting the outcomes of the research in context. Research limitations/implications - This qualitative study provides detailed understandings that could provide the basis for a wider quantitative study that would provide greater coverage of the sector, thus reinforcing the outcomes. Practical implications - The study will be relevant to practising CEOs who are considering the range of options offered by OI. Originality/value - While large firms are adopting OI strategies, less is known about the OI strategies developed in SMEs. The study addresses that gap. The life sciences context is also novel.
引用
收藏
页码:210 / 229
页数:20
相关论文
共 50 条
[21]   The Relevance of Different Open Innovation Strategies for R&D Performers [J].
Santamaria, Lluis ;
Jesus Nieto, Maria ;
Barge-Gil, Andres .
CUADERNOS DE ECONOMIA Y DIRECCION DE LA EMPRESA, 2010, (45) :93-114
[22]   Strategic R&D alliance factors that impact innovation success in the biotechnology industry [J].
Kim, Kelly Y. .
INTERNATIONAL JOURNAL OF TECHNOLOGY MANAGEMENT, 2012, 59 (1-2) :116-138
[23]   The dynamics of exports and R&D in SMEs [J].
Esteve-Perez, Silviano ;
Rodriguez, Diego .
SMALL BUSINESS ECONOMICS, 2013, 41 (01) :219-240
[24]   Open innovation as the missing link in the mediated model among R&D educational heterogeneity, innovation and performance [J].
Leskovec, Fabijan ;
Cerne, Matej ;
Peljhan, Darja .
JOURNAL OF INNOVATION & KNOWLEDGE, 2025, 10 (01)
[25]   Influence of government R&D support and inter-firm collaborations on innovation in Korean biotechnology SMEs [J].
Kang, Kyung-Nam ;
Park, Hayoung .
TECHNOVATION, 2012, 32 (01) :68-78
[26]   Relationship between R&D subsidies and R&D collaboration in promoting firm innovation [J].
Dong, Huiping ;
Guo, Yating ;
Shi, Xing ;
Du, Shaofu .
JOURNAL OF TECHNOLOGY TRANSFER, 2024,
[27]   Interactive learning - The key to innovation in non-R&D-intensive SMEs? A cluster analysis approach [J].
Thoma, Jorg ;
Zimmermann, Volker .
JOURNAL OF SMALL BUSINESS MANAGEMENT, 2020, 58 (04) :747-776
[28]   Substitutability in R&D and Open Innovation: Why Competing Firms Face a Paradox of Openness? [J].
da Silva, Mario A. P. M. .
JOURNAL OF THE KNOWLEDGE ECONOMY, 2024, 15 (02) :5204-5229
[29]   Innovation in pharmaceutical R&D: mapping the research landscape [J].
Romasanta, Angelo Kenneth S. ;
van der Sijde, Peter ;
Van Muijlwijk-Koezen, Jacqueline .
SCIENTOMETRICS, 2020, 125 (03) :1801-1832
[30]   Open innovation: A real option to restore value to the biopharmaceutical R&D [J].
Lo Nigro, Giovanna ;
Morreale, Azzurra ;
Enea, Gianluca .
INTERNATIONAL JOURNAL OF PRODUCTION ECONOMICS, 2014, 149 :183-193